Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Seger

Clinical Cardiac Electrophysiology Houston, TX Medical Doctor

NPI 1104846450 CMS profile 185640

6624 Fannin St, Ste 1910, Houston, TX 77030

Open in the dashboard

General payments

$147,101

1,534 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$153,118 paid to institutions, not to them · program years 2019–2022

Through program year 2025, John Seger of Houston, TX is reported in the CMS Open Payments database as having received $147,101 across 1,534 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $153,118 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,725 116
2024 General $7,029 190
2023 General $12,685 278
2022 General $52,267 291
2021 General $24,857 284
2020 General $17,158 151
2019 General $28,381 224

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Seger
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to John Seger were reported at $4,725. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year John Seger Clinical Cardiac Electrophysiology median Middle half National median
2019 $28,381 $2,361 $585–$8,260 $163
2020 $17,158 $993 $247–$4,351 $114
2021 $24,857 $1,185 $326–$4,739 $132
2022 $52,267 $2,073 $554–$6,789 $149
2023 $12,685 $2,568 $759–$8,159 $160
2024 $7,029 $2,557 $703–$7,403 $164
2025 $4,725 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $54,865 222 payments
  2. Sanofi-Aventis U.S. LLC $34,701 58 payments
  3. Medtronic, Inc. $19,474 231 payments
  4. Abbott Laboratories $10,365 240 payments
  5. Biosense Webster, Inc. $8,373 252 payments
  6. Pfizer Inc. $7,560 117 payments
  7. Medtronic Vascular, Inc. $2,681 84 payments
  8. Impulse Dynamics (USA) Inc. $1,407 26 payments
  9. E.R. Squibb & Sons, L.L.C. $1,402 90 payments
  10. Boston Scientific Corporation $1,195 42 payments
  11. Other $5,078 172 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $92,690 46 payments
  2. Food and Beverage $36,602 1,446 payments
  3. Travel and Lodging $9,952 36 payments
  4. Consulting Fee $7,810 3 payments
  5. Education $30 2 payments
  6. Entertainment $17 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $54,865 222 payments
  2. MULTAQ Cardiology/Vascular Diseases $19,194 30 payments
  3. Carto 3 $8,450 247 payments
  4. MULTAQ Cardiovascular $8,024 14 payments
  5. MULTAQ Cardiology/Vascular Diseases $7,439 11 payments
  6. ELIQUIS $7,023 98 payments
  7. Micra $5,832 38 payments
  8. ENSITE PRECISION $1,866 56 payments
  9. EVERA MRI XT DR SURESCAN $1,511 6 payments
  10. AMPLATZER $1,344 3 payments
  11. Other $26,501 921 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

3,794

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$1,510,017

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

40.1%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,006 $1,040,369
Xarelto Rivaroxaban Brand 330 $368,048
Multaq Dronedarone Hcl Brand 62 $51,049
Metoprolol Succinate Generic 951 $17,185
Dofetilide Generic 54 $9,392
Amiodarone Hcl Generic 422 $9,120
Nebivolol Hcl Generic 63 $2,968
Digoxin Generic 63 $1,326
Amlodipine Besylate Generic 93 $884
Rosuvastatin Calcium Generic 39 $857

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$447,340

Medicare's payments for the services billed

Medicare patients

987

Average age 78

Services billed

7,571

355 women, 632 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Ischemic heart disease 66%
Heart failure 47%
Arthritis 47%
Chronic kidney disease 32%
Diabetes 31%
Cancer 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
$435 330 —
ELIQUIS
$332 1,006 —
CAMZYOS
$184 — —
NURTEC ODT
$68 — —
PAXLOVID
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

1,534 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record